Key result
The VALID trial is a planned randomized study designed to evaluate whether high-dose valsartan reduces post-myocardial infarction ventricular remodeling more effectively than usual-dose valsartan over 12 months.
Why the study?
Does a maximal tolerable dose of valsartan improve post-MI ventricular remodeling compared to a usual dose in patients with left ventricular dysfunction following a first acute STEMI?
RCT (n=1,116)
Open-label, single-blinded (central core laboratory for echocardiography)
1:2 ratio via centralized web-based tool
Yes
Does a maximal tolerable dose of valsartan improve post-MI ventricular remodeling compared to a usual dose in patients with left ventricular dysfunction following a first acute STEMI?
This study protocol describes a randomized trial to evaluate whether titrating valsartan to a maximal tolerable dose improves post-MI ventricular remodeling compared to a standard 80 mg/day dose.
Answers are grounded in this paper and cite their sources.
VALID trial will test high- vs usual-dose valsartan on post-MI remodeling; leaves open optimal dosing until completion.
BACKGROUND: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is more efficacious compared to the lower dose that is commonly used in clinical practice. METHOD/DESIGN: Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio. Echocardiographic analysis for quantifying post-MI ventricular remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at fixed times. DISCUSSION: VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the management of patients after MI. The results will be available by 2012. TRIAL REGISTRATION: NCT01340326.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2011) conducted an RCT in ST-elevation myocardial infarction with left ventricular dysfunction (n=1,116). Valsartan vs. 80 mg/day (40 mg twice a day) was evaluated on Change in the left ventricular volume index measured by echocardiography from baseline to 12-month follow-up. The VALID trial is a planned randomized study designed to evaluate whether high-dose valsartan reduces post-myocardial infarction ventricular remodeling more effectively than usual-dose valsartan over 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: